139 related articles for article (PubMed ID: 26851026)
1. Synergisitic and Antagonistic AML Cell Type-specific Responses to 5-Aza-2-deoxycitidine and 1-h-D-Arabinofuranoside.
Elmoneim AA; Heuston E; Wai DH; Triche T; Arceci RJ
Anticancer Res; 2016 Feb; 36(2):691-6. PubMed ID: 26851026
[TBL] [Abstract][Full Text] [Related]
2. Effect of cytarabine and decitabine in combination in human leukemic cell lines.
Qin T; Youssef EM; Jelinek J; Chen R; Yang AS; Garcia-Manero G; Issa JP
Clin Cancer Res; 2007 Jul; 13(14):4225-32. PubMed ID: 17634552
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic action of decitabine (5-aza-2'-deoxycytidine) is more effective against acute myeloid leukemia than cytotoxic action of cytarabine (ARA-C).
Momparler RL; Côté S; Momparler LF
Leuk Res; 2013 Aug; 37(8):980-4. PubMed ID: 23660386
[TBL] [Abstract][Full Text] [Related]
4. Combination screening in vitro identifies synergistically acting KP372-1 and cytarabine against acute myeloid leukemia.
Österroos A; Kashif M; Haglund C; Blom K; Höglund M; Andersson C; Gustafsson MG; Eriksson A; Larsson R
Biochem Pharmacol; 2016 Oct; 118():40-49. PubMed ID: 27565890
[TBL] [Abstract][Full Text] [Related]
5. Defective expression of deoxycytidine kinase in cytarabine-resistant acute myeloid leukemia cells.
Song JH; Kim SH; Kweon SH; Lee TH; Kim HJ; Kim HJ; Kim TS
Int J Oncol; 2009 Apr; 34(4):1165-71. PubMed ID: 19287976
[TBL] [Abstract][Full Text] [Related]
6. Potentiation of in vitro ara-C cytotoxicity by ribonucleotide reductase inhibitors, cyclin-dependent kinase modulators and the DNA repair inhibitor aphidicolin in paediatric acute myeloid leukaemia.
Hubeek I; Peters GJ; Broekhuizen AJ; Sargent J; Gibson BE; Creutzig U; Kaspers GJ
Br J Haematol; 2005 Oct; 131(2):219-22. PubMed ID: 16197453
[TBL] [Abstract][Full Text] [Related]
7. Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies.
Herold N; Rudd SG; Ljungblad L; Sanjiv K; Myrberg IH; Paulin CB; Heshmati Y; Hagenkort A; Kutzner J; Page BD; Calderón-Montaño JM; Loseva O; Jemth AS; Bulli L; Axelsson H; Tesi B; Valerie NC; Höglund A; Bladh J; Wiita E; Sundin M; Uhlin M; Rassidakis G; Heyman M; Tamm KP; Warpman-Berglund U; Walfridsson J; Lehmann S; Grandér D; Lundbäck T; Kogner P; Henter JI; Helleday T; Schaller T
Nat Med; 2017 Feb; 23(2):256-263. PubMed ID: 28067901
[TBL] [Abstract][Full Text] [Related]
8. The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells.
Almstedt M; Blagitko-Dorfs N; Duque-Afonso J; Karbach J; Pfeifer D; Jäger E; Lübbert M
Leuk Res; 2010 Jul; 34(7):899-905. PubMed ID: 20381863
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy with azacitidine, etoposide, and cytarabine in the treatment of elderly acute myeloid leukemia patients: A single center experience.
Onec B; Okutan H; Albayrak M; Can ES; Aslan V; Koluman BU; Kosemehmetoglu OS; Albayrak A
J Cancer Res Ther; 2018; 14(5):1105-1111. PubMed ID: 30197357
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cells.
Li P; Diab S; Yu M; Adams J; Islam S; Basnet SK; Albrecht H; Milne R; Wang S
Oncotarget; 2016 Aug; 7(35):56811-56825. PubMed ID: 27462781
[TBL] [Abstract][Full Text] [Related]
11. SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.
Schneider C; Oellerich T; Baldauf HM; Schwarz SM; Thomas D; Flick R; Bohnenberger H; Kaderali L; Stegmann L; Cremer A; Martin M; Lohmeyer J; Michaelis M; Hornung V; Schliemann C; Berdel WE; Hartmann W; Wardelmann E; Comoglio F; Hansmann ML; Yakunin AF; Geisslinger G; Ströbel P; Ferreirós N; Serve H; Keppler OT; Cinatl J
Nat Med; 2017 Feb; 23(2):250-255. PubMed ID: 27991919
[TBL] [Abstract][Full Text] [Related]
12. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
[TBL] [Abstract][Full Text] [Related]
13. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
Avramis IA; Laug WE; Sausville EA; Avramis VI
Cancer Chemother Pharmacol; 2003 Oct; 52(4):307-18. PubMed ID: 12827297
[TBL] [Abstract][Full Text] [Related]
14. Azacitidine and low-dose cytarabine in palliative patients with acute myeloid leukemia and high bone marrow blast counts--a retrospective single-center experience.
Radujkovic A; Dietrich S; Bochtler T; Krämer A; Schöning T; Ho AD; Dreger P; Luft T
Eur J Haematol; 2014 Aug; 93(2):112-7. PubMed ID: 24628527
[TBL] [Abstract][Full Text] [Related]
15. Differential TERT promoter methylation and response to 5-aza-2'-deoxycytidine in acute myeloid leukemia cell lines: TERT expression, telomerase activity, telomere length, and cell death.
Pettigrew KA; Armstrong RN; Colyer HA; Zhang SD; Rea IM; Jones RE; Baird DM; Mills KI
Genes Chromosomes Cancer; 2012 Aug; 51(8):768-80. PubMed ID: 22517724
[TBL] [Abstract][Full Text] [Related]
16. [Experimental study of cord blood plasma enhancing the anti-leukemia effect of Ara-C].
Zhang X; Chen Y; Wang X
Zhonghua Xue Ye Xue Za Zhi; 1999 May; 20(5):229-31. PubMed ID: 11601208
[TBL] [Abstract][Full Text] [Related]
17. Circumvention of ara-C resistance by aphidicolin in blast cells from patients with AML.
Sargent JM; Elgie AW; Williamson CJ; Lewandowicz GM; Taylor CG
Br J Cancer; 2001 Mar; 84(5):680-5. PubMed ID: 11237390
[TBL] [Abstract][Full Text] [Related]
18. DNA Methylation-Based Epigenetic Repression of SLC22A4 Promotes Resistance to Cytarabine in Acute Myeloid Leukemia.
Buelow DR; Anderson JT; Pounds SB; Shi L; Lamba JK; Hu S; Gibson AA; Goodwin EA; Sparreboom A; Baker SD
Clin Transl Sci; 2021 Jan; 14(1):137-142. PubMed ID: 32905646
[TBL] [Abstract][Full Text] [Related]
19. The effects of cytarabine combined with ginsenoside compound K synergistically induce DNA damage in acute myeloid leukemia cells.
Qi W; Yan X; Xu X; Song B; Sun L; Zhao D; Sun L
Biomed Pharmacother; 2020 Dec; 132():110812. PubMed ID: 33059263
[TBL] [Abstract][Full Text] [Related]
20. Induction of cytosine arabinoside-resistant human myeloid leukemia cell death through autophagy regulation by hydroxychloroquine.
Kim Y; Eom JI; Jeung HK; Jang JE; Kim JS; Cheong JW; Kim YS; Min YH
Biomed Pharmacother; 2015 Jul; 73():87-96. PubMed ID: 26211587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]